Essential Principles in Prodrugs Design
Abstract
This research aims to explore the design and application of prodrugs as an effective strategy in drug development. Prodrugs are chemically modified compounds designed to improve stability, solubility, and permeability, which are activated through enzymatic or chemical processes. This study reviews various types of prodrugs, including bioprecursors, targeted, mixed, and mutual prodrugs. The methods used in this research involve literature analysis and case studies focusing on prodrugs that have successfully enhanced bioavailability and therapeutic efficacy. The results indicate that the prodrug strategy can significantly overcome pharmacokinetic and pharmacodynamic limitations of drugs, extend the duration of effects, and improve target selectivity. The conclusion of this research confirms that prodrug design is a promising approach in enhancing modern drug therapy, particulaly in the context of cancer treatment.
References
Abhinav P., Suresh C., Ruchi T., Ashish S., and Gaurav T., Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery. J. Med Chem. (2018).
Antonio T., Chung M., Lucia F., Rafael V. and Ferreira E., Advances in Prodrug Design. Mini-Reviews In Medicinal Chemistry; 5, 893-914 893, (2005).
Bhosle D., Bharambe S., Gairola N. , Suneela S., Mutual prodrug concept: Fundamentals and Applications. Indian J. Pharm. Sci. ; 68 (3): 286-294, (2006).
Daniela H., Guilherme F., Diego E., Thais R., J., and Chung M., The Prodrug Approach: A Successful Tool for Improving Drug Solubility. J. Molecules; 21(1): 42, (2016).
Ettmayer P., Amidon G., Clement B. et al. Lessons learned from marketed and investigational prodrugs. J. Med Chem.;47(10):2393-2240, (2004).
Felix K., Ivonne A., Claudia R and Andre W., Prodrug Strategies in Anticancer Chemotherapy. J. ChemMedChem ; 3, 20 – 53,(2008).
Han H., Targeted prodrug design to optimize drug delivery. G. L. AAPS Pharm. Sci. 2, E6 ; ,(2000).
Jilani J., Idkaidek N., Alzoubi K., Synthesis, In Vitro and In Vivo Evaluation of the N-ethoxycarbonyl-
Kamal S., Jeetendra K., Nagendra S., Neeraj U., Sushant K., and Pradeep M., Prodrugs of NSAIDs. The Open Medicinal Chemistry Journal; 11(1),146-195, (2017).
Kelemen H., Hancu G., Rusu A., Varga E., Szekely S., Prodrug Strategy in Drug Development. Acta Medica Marisiensis;62(3):356-362, (2016)
Kuei-Meng W., A New Classification of Prodrugs: Regulatory Perspectives. J. Pharmaceuticals ; 2(3): 77–81, (2009).
morpholine Ester of Diclofenac as a Prodrug. Pharmaceuticals (Basel);7(4):453-63, (2014).
Pandey P.; Pandey S. Synthesis, characterization and pharmacological screening: Mutual amide prodrug of ketorolac-glucosamine. J. Med.Sci. ; 13, 36-42, (2013).
Povl K.; Hans B. A Textbook of Drug Design and Development, Harwood Academic Publishers: Academic, (1991).
Prokai L., Prokai K. and Bodor N. Targeting drugs to the brain by redox chemical delivery systems. J. Med. Res. Rev.; 20,367,(2000).
Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov.;7:255-270, (2008).
Roberto P., Michelle C., Silvio B., Monique G., Elizabeth I., Prodrugs available on the Brazilian Pharmaceutical market and their corresponding bioactivation pathways. Braz. J. Pharm. Sci. ; 46 (3), (2010).
Suneela D., Astha J., Kunal T. Design and applications of bio-precursors: a retro-metabolic approach J. PubMed;15(3):291-325, (2014).
Testa B., Mayer J.m Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology, Wiley-VCH, (2003).
Testa, B., Prodrug research: futile or fertile? Biochem. Pharmacol. ; 68, 2097,(2004).
Vlieghe P., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Kraus J., Synthesis of New Covalently Bound K-Carrageenan−AZT Conjugates with Improved Anti-HIV Activities. J. Medicinal Chemistry; 45(6), 1275–1283,(2002).
Wermuth, C. In The Practice of Medicinal Chemistry, Academic Press: London, (2011).
